Metabolomics Blood Test
Early Screening for Pre-Invasive Cancer
Key Facts
About Austin Biosciences
Austin Biosciences is developing a first-of-its-kind, metabolomics-based diagnostic platform designed to transform cancer care through early detection and personalized treatment monitoring. The company's core technology, exclusively licensed from the University of Minnesota, enables sensitive screening from a simple blood draw and supports applications in therapy monitoring, recurrence detection, and drug discovery. ABS is positioning itself to address critical unmet needs in oncology by providing tools for earlier intervention and more tailored therapeutic strategies.
View full company profileAbout Austin Biosciences
Austin Biosciences is developing a first-of-its-kind, metabolomics-based diagnostic platform designed to transform cancer care through early detection and personalized treatment monitoring. The company's core technology, exclusively licensed from the University of Minnesota, enables sensitive screening from a simple blood draw and supports applications in therapy monitoring, recurrence detection, and drug discovery. ABS is positioning itself to address critical unmet needs in oncology by providing tools for earlier intervention and more tailored therapeutic strategies.
View full company profileAbout Austin Biosciences
Austin Biosciences is developing a first-of-its-kind, metabolomics-based diagnostic platform designed to transform cancer care through early detection and personalized treatment monitoring. The company's core technology, exclusively licensed from the University of Minnesota, enables sensitive screening from a simple blood draw and supports applications in therapy monitoring, recurrence detection, and drug discovery. ABS is positioning itself to address critical unmet needs in oncology by providing tools for earlier intervention and more tailored therapeutic strategies.
View full company profileAbout Austin Biosciences
Austin Biosciences is developing a first-of-its-kind, metabolomics-based diagnostic platform designed to transform cancer care through early detection and personalized treatment monitoring. The company's core technology, exclusively licensed from the University of Minnesota, enables sensitive screening from a simple blood draw and supports applications in therapy monitoring, recurrence detection, and drug discovery. ABS is positioning itself to address critical unmet needs in oncology by providing tools for earlier intervention and more tailored therapeutic strategies.
View full company profile